This led to a multicenter, phase II study to evaluate the addition of etoposide to BV + CHP (CHEP-BV), followed by BV consolidation in patients with newly diagnosed CD30-expressing PTCL. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.